ClinicalTrials.gg
CompletedNCT02393937Updated Sep 3, 2020

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

A Phase 3 interventional study of Reference: Metronidazole Gel 1% and Test: Metronidazole Gel 1% in Papulopustular Rosacea and Erythematotelangiectatic Rosacea, sponsored by bioRASI, LLC. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-03.

Sponsored by bioRASI, LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
963
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 145 studies in Rosacea with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Rosacea · United States.

Enrollment
5th of 137
963 · median 78
Started
2015
with 5 others
Phase 3
32 of 145
none open now
Registered
70th of 145
by date

Among the 145 studies in Rosacea with a site in United States, this one is the 5th largest by enrollment of the 137 interventional ones that give a count, is one of 6 that started in 2015, is one of 32 in phase 3, and was the 70th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

8 of the 145 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Rosacea with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.

03

Conditions studied

  • Papulopustular Rosacea
  • Erythematotelangiectatic Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female subjects with at least 18 years of age;
  • Read and signed ICF;
  • Clinical Diagnosis of Rosacea;

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, lactating or of who are not using or do not agree to use an acceptable form of ;
  • Any skin condition that would interfere with treatment of rosacea
  • Use of prohibited medications
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
963 participants (actual)

Study arms

  • Experimental
    Test: Metronidazole Gel 1%

    Metronidazole Gel 1% once daily for 70 days.

    Drug: Test: Metronidazole Gel 1%

  • Active comparator
    Reference: Metronidazole Gel 1%

    Metronidazole Gel, 1% (MetroGel) Galderma S.A. once daily for 70 days.

    Drug: Reference: Metronidazole Gel 1%

  • Placebo comparator
    Placebo

    Placebo Gel once daily for 70 days.

    Drug: Placebo Gel

Interventions

  • Participants are assigned to one of three groups in parallel for the duration of the study

    Also known as: MetroGel

  • Participants are assigned to one of three groups in parallel for the duration of the study

  • DrugPlacebo Gel

    Participants are assigned to one of three groups in parallel for the duration of the study

06

What researchers measure

Primary outcomes

  1. To compare the test and reference products of metronidazole topical gel 1% with regard to the mean percent change from Baseline of the inflammatory lesion counts of rosacea.

    Time frame: 70 Days

Secondary outcomes

  1. To compare the test and reference product of metronidazole topical gel 1% with regard to the Investigator's Global Evaluation (IGE) of disease severity

    Time frame: 70 Days

07

Study locations

27 sites
  • Los Angeles, California 90036, United States
  • San Diego, California 92121, United States
  • Boca Raton, Florida 33486, United States
  • Clearwater, Florida 33761, United States
  • Miami, Florida 33126, United States
  • Miami, Florida 33136, United States
  • Miramar, Florida 33027q, United States
  • Ocala, Florida 34471, United States
  • Tampa, Florida 33634, United States
  • Lexington, Kentucky 40509, United States
  • Watertown, Massachusetts 02472, United States
  • Las Vegas, Nevada 89104, United States
  • New York, New York 10075, United States
  • High Point, North Carolina 27262, United States
  • Raleigh, North Carolina 27612, United States
  • Cincinnati, Ohio 45246, United States
  • Philadelphia, Pennsylvania 19103, United States
  • Warwick, Rhode Island 02886, United States
  • Mount Pleasant, South Carolina 29464, United States
  • Austin, Texas 78759, United States
  • El Paso, Texas 79902, United States
  • Houston, Texas 77055, United States
  • Pflugerville, Texas 78660, United States
  • Plano, Texas 75093, United States
  • San Antonio, Texas 78229, United States
  • Arlington, Virginia 22203, United States
  • Norfolk, Virginia 23507, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Jul 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2015
First posted
Mar 20, 2015
Start
Feb 2015
Primary completionActual
Jul 2015
CompletionActual
Oct 2015
Results delay requested
Aug 31, 2020
Last update
Sep 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02393937
Lead sponsor
bioRASI, LLC
Responsible party
Sponsor
First posted
Mar 20, 2015
Start date
Feb 2015
Primary completion
Jul 2015
Completion
Oct 2015
Last update
Sep 3, 2020
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion